| 93865-4 |
Conference note |
Find |
{Setting} |
Pt |
Doc |
General medicine.team |
|
ACTIVE |
General medicine Team Conference note |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
93865-4 |
|
General medicine.team |
|
|
Both |
|
|
|
0 |
Gen med Team Conf note |
|
|
|
|
|
Conf note; DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; Gen med Team; notes; Point in time; Random; Visit note |
2.78 |
2.67 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 93866-2 |
C4 nephritic factor |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
C4 nephritic factor [Presence] in Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
93866-2 |
|
|
|
|
Both |
|
|
|
0 |
C4 NeF SerPl Ql |
|
|
|
|
|
C4 NeF; C4NEF; Complement.C4 Nephritic; Fac; Fact; HEMATOLOGY/CELL COUNTS; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.67 |
2.67 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 93867-0 |
Gamma aminobutyrate B receptor Ab |
PrThr |
Ser |
Pt |
Ord |
CBA IFA |
|
ACTIVE |
GABABR Ab [Presence] in Serum by Cell binding immunofluorescent assay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
93867-0 |
|
CBA IFA |
|
|
Both |
|
|
|
0 |
GABABR Ab Ser Ql CBA IFA |
|
|
|
|
|
4-aminobutanoic acid; 4-aminobutyrate; 4-aminobutyric acid; ABS; Aby; Aminobutric; Aminobutyric; Amino-n-butyrate; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; GABA; GABABR; GABABR Ab; Gamma aminobutyric acid; Gamma amino-butyric acid; Gamma amino-n-butyrate; Gamma amino-n-butyric acid; Indirect Fluorescence Antibody; Ordinal; Piperidic acid; Point in time; PR; QL; Qual; Qualitative; Random; Rec; Recept; Receptors; Recp; Recptr; Screen; Serology; Serum; SR |
2.69 |
2.67 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 93868-8 |
Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 2 Ab |
PrThr |
Ser |
Pt |
Ord |
CBA IFA |
|
ACTIVE |
AMPAR2 Ab [Presence] in Serum by Cell binding immunofluorescent assay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
93868-8 |
|
CBA IFA |
|
|
Both |
|
|
|
0 |
AMPAR2 Ab Ser Ql CBA IFA |
|
|
|
|
|
ABS; Aby; Alfa; AMPA Receptor; AMPAR2; AMPAR2 Ab; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; GluA2; GluR2; GluR-B; Hydrox; II; III; Indirect Fluorescence Antibody; Limbic encephalitis; OH; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Rec; Recept; Receptors; Recp; Recptr; Screen; Serology; Serum; SR |
2.69 |
2.67 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 93869-6 |
Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 1 Ab |
PrThr |
Ser |
Pt |
Ord |
CBA IFA |
|
ACTIVE |
AMPAR1 Ab [Presence] in Serum by Cell binding immunofluorescent assay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
93869-6 |
|
CBA IFA |
|
|
Both |
|
|
|
0 |
AMPAR1 Ab Ser Ql CBA IFA |
|
|
|
|
|
ABS; Aby; Alfa; AMPA Receptor; AMPAR1; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; GluA1; GluR1; GluR-A; Hydrox; i; III; Indirect Fluorescence Antibody; Limbic encephalitis; OH; Ordinal; Point in time; PR; QL; Qual; Qualitative; Quisqualate Receptor; Random; Rec; Recept; Receptors; Recp; Recptr; Screen; Serology; Serum; SR |
2.69 |
2.67 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 9387-2 |
Procyclidine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Procyclidine [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
9387-2 |
|
|
|
|
Both |
|
|
|
0 |
Procyclidine SerPl-mCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Kemadrin; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
1.0i |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 93870-4 |
N-methyl-D-aspartate receptor subunit 1 Ab |
PrThr |
Ser |
Pt |
Ord |
CBA IFA |
|
ACTIVE |
NMDAR subunit 1 Ab [Presence] in Serum by Cell binding immunofluorescent assay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
93870-4 |
|
CBA IFA |
|
|
Both |
|
|
|
0 |
NMDAR1 Ab Ser Ql CBA IFA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Asp; Aspartic acid; Autoantibodies; Autoantibody; Dextro; Encephalitis; Glutamate receptor ionotropic, NMDA 1; i; Indirect Fluorescence Antibody; NMDA receptor; NMDAR; NMDAR1; N-Methylaspartate Receptors; N-Methyl-D-aspartic Acid; Ordinal; Paraneoplastic syndrome; Point in time; PR; QL; Qual; Qualitative; Random; Rec; Recept; Receptors; Recp; Recptr; Screen; Serology; Serum; SR |
2.69 |
2.67 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 93871-2 |
Borrelia miyamotoi Ab.IgG+IgM |
Imp |
Ser/Plas |
Pt |
Nom |
|
|
ACTIVE |
Borrelia miyamotoi IgG+IgM Ab [Interpretation] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
93871-2 |
|
|
|
|
Observation |
|
|
|
0 |
B miyamotoi IgG+IgM SerPl-Imp |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; B miyamotoi; Immune globulin G; Immune globulin M; Immunoglobulin G; Immunoglobulin M; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Microbiology; Nominal; Pl; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; TBRF; Tick Borne Diseases; tick-borne relapsing fever |
2.71 |
2.67 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 93872-0 |
Tamoxifen metabolites pattern |
Imp |
Ser/Plas |
Pt |
Nom |
|
|
ACTIVE |
Tamoxifen metabolites pattern [Interpretation] in Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
93872-0 |
|
|
|
|
Observation |
|
|
|
0 |
Tamoxifen metab pattern SerPl-Imp |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Metabolite; Metb; Nolvadex; Nominal; Pl; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tamoxifen metab pattern |
2.67 |
2.67 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 93873-8 |
Borrelia miyamotoi Ab.IgG |
ACnc |
Ser/Plas |
Pt |
Qn |
IA |
|
ACTIVE |
Borrelia miyamotoi IgG Ab [Units/volume] in Serum or Plasma by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
EIA index |
|
|
|
|
|
|
MICRO |
|
93873-8 |
|
IA |
|
|
Both |
|
|
|
0 |
B miyamotoi IgG SerPl IA-aCnc |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B miyamotoi; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; Immune globulin G; Immunoglobulin G; MEIA; Microbiology; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; SUDS; TBRF; Tick Borne Diseases; tick-borne relapsing fever |
2.71 |
2.67 |
|
|
|
|
|
|
|
{EIA_index} |
|
|
|
0 |
| 93874-6 |
Borrelia miyamotoi Ab.IgM |
ACnc |
Ser/Plas |
Pt |
Qn |
IA |
|
ACTIVE |
Borrelia miyamotoi IgM Ab [Units/volume] in Serum or Plasma by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
EIA index |
|
|
|
|
|
|
MICRO |
|
93874-6 |
|
IA |
|
|
Both |
|
|
|
0 |
B miyamotoi IgM SerPl IA-aCnc |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B miyamotoi; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; Immune globulin M; Immunoglobulin M; MEIA; Microbiology; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; SUDS; TBRF; Tick Borne Diseases; tick-borne relapsing fever |
2.71 |
2.67 |
|
|
|
|
|
|
|
{EIA_index} |
|
|
|
0 |
| 93875-3 |
Phosphohistone H3 |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
Phosphohistone H3 [Presence] in Tissue by Immune stain |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATH |
|
93875-3 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
PHH3 Tiss Ql ImStn |
|
|
|
|
|
IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ordinal; PATHOLOGY; PHH3; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified |
2.67 |
2.67 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 93876-1 |
Ceramide risk score |
Score |
Plas |
Pt |
Qn |
Calculated |
|
ACTIVE |
Ceramide risk score in Plasma by calculation |
|
ADD |
DefinitionDescription |
|
|
score |
|
|
|
|
|
|
CHEM |
|
93876-1 |
|
Calculated |
|
|
Observation |
|
|
|
0 |
Ceramide risk score Plas Calc |
|
|
|
|
|
Calc; Calculation; Chemistry; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Scale |
2.67 |
2.67 |
|
|
|
|
|
|
|
{score} |
|
|
|
0 |
| 93877-9 |
N-Nervonoylsphingosine/N-Lignoceroylsphingosine |
SRto |
Plas |
Pt |
Qn |
|
|
ACTIVE |
N-Nervonoylsphingosine/N-Lignoceroylsphingosine [Molar ratio] in Plasma |
|
ADD |
DefinitionDescription |
|
|
ratio |
|
|
|
|
|
|
CHEM |
|
93877-9 |
|
|
|
|
Both |
|
|
|
0 |
C24:1 ceramide/C24 ceramide Plas-sRto |
|
|
|
|
|
C24 ceramide; C24:1 ceramide; Chemistry; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio |
2.67 |
2.67 |
|
|
|
|
|
|
|
{ratio} |
|
|
|
0 |
| 93878-7 |
N-Stearoylsphingosine/N-Lignoceroylsphingosine |
SRto |
Plas |
Pt |
Qn |
|
|
ACTIVE |
N-Stearoylsphingosine/N-Lignoceroylsphingosine [Molar ratio] in Plasma |
|
ADD |
DefinitionDescription |
|
|
ratio |
|
|
|
|
|
|
CHEM |
|
93878-7 |
|
|
|
|
Both |
|
|
|
0 |
C18 ceramide/C24 ceramide Plas-sRto |
|
|
|
|
|
C18 Cer; C18 ceramide; C24 ceramide; Chemistry; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio |
2.67 |
2.67 |
|
|
|
|
|
|
|
{ratio} |
|
|
|
0 |
| 93879-5 |
N-Palmitoylsphingosine/N-Lignoceroylsphingosine |
SRto |
Plas |
Pt |
Qn |
|
|
ACTIVE |
N-Palmitoylsphingosine/N-Lignoceroylsphingosine [Molar ratio] in Plasma |
|
ADD |
DefinitionDescription |
|
|
ratio |
|
|
|
|
|
|
CHEM |
|
93879-5 |
|
|
|
|
Both |
|
|
|
0 |
C16 ceramide/C24 ceramide Plas-sRto |
|
|
|
|
|
C16 ceramide; C24 ceramide; Chemistry; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio |
2.67 |
2.67 |
|
|
|
|
|
|
|
{ratio} |
|
|
|
0 |
| 9388-0 |
Propylthiouracil |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Propylthiouracil [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
9388-0 |
|
|
|
|
Both |
|
|
|
0 |
Propylthiouracil SerPl-mCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; PTU; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
1.0i |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 93880-3 |
N-Nervonoylsphingosine |
SCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
N-Nervonoylsphingosine [Moles/volume] in Plasma |
|
ADD |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
93880-3 |
|
|
|
|
Both |
|
|
|
0 |
C24:1 ceramide Plas-sCnc |
|
|
|
|
|
C24:1 ceramide; Chemistry; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration |
2.67 |
2.67 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 93881-1 |
N-Stearoylsphingosine |
SCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
N-Stearoylsphingosine [Moles/volume] in Plasma |
|
ADD |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
93881-1 |
|
|
|
|
Both |
|
|
|
0 |
C18 ceramide Plas-sCnc |
|
|
|
|
|
C18 Cer; C18 ceramide; Chemistry; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration |
2.67 |
2.67 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 93882-9 |
N-Palmitoylsphingosine |
SCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
N-Palmitoylsphingosine [Moles/volume] in Plasma |
|
ADD |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
93882-9 |
|
|
|
|
Both |
|
|
|
0 |
C16 ceramide Plas-sCnc |
|
|
|
|
|
C16 ceramide; Chemistry; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration |
2.67 |
2.67 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 93883-7 |
Ceramide panel |
- |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Ceramide panel - Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
93883-7 |
|
|
|
|
Order |
|
|
|
0 |
Ceramide Pnl Plas |
|
|
|
|
|
Ceramide Pnl; Chemistry; Pan; PANEL.CHEMISTRY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.68 |
2.67 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 93884-5 |
Methane/Expired gas^2H post dose carbohydrate |
VFr |
Exhl gas |
Pt |
Qn |
|
|
ACTIVE |
Methane/Expired gas [Volume Fraction] in Exhaled gas --2 hours post dose carbohydrate |
|
ADD |
DefinitionDescription |
|
|
ppm |
|
|
|
|
|
|
CHAL |
|
93884-5 |
|
|
|
|
Observation |
|
|
|
0 |
Breath methane 2h p carb |
|
|
|
|
|
120 min; 120 minutes; 120min; 2 hours; 2h p carb; After; Breath; CHEMISTRY.CHALLENGE TESTING; ExG; Exhaled gas; Exhaled gas (=breath); Gases; p carb; p dose; Percent; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Volfr; Volume fraction |
2.67 |
2.67 |
|
|
|
|
|
|
|
[ppm] |
|
|
|
0 |
| 93885-2 |
Methane/Expired gas^1.5H post dose carbohydrate |
VFr |
Exhl gas |
Pt |
Qn |
|
|
ACTIVE |
Methane/Expired gas [Volume Fraction] in Exhaled gas --1.5 hours post dose carbohydrate |
|
ADD |
DefinitionDescription |
|
|
ppm |
|
|
|
|
|
|
CHAL |
|
93885-2 |
|
|
|
|
Observation |
|
|
|
0 |
Breath methane 1.5h p carb |
|
|
|
|
|
1 1/2 hours; 1 1/2 HR; 1.5h p carb; 1.5Hr; 90 min; 90 minutes; 90M; 90min; After; Breath; CHEMISTRY.CHALLENGE TESTING; ExG; Exhaled gas; Exhaled gas (=breath); Gases; p carb; p dose; Percent; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Volfr; Volume fraction |
2.67 |
2.67 |
|
|
|
|
|
|
|
[ppm] |
|
|
|
0 |
| 93886-0 |
Methane/Expired gas^1H post dose carbohydrate |
VFr |
Exhl gas |
Pt |
Qn |
|
|
ACTIVE |
Methane/Expired gas [Volume Fraction] in Exhaled gas --1 hour post dose carbohydrate |
|
ADD |
DefinitionDescription |
|
|
ppm |
|
|
|
|
|
|
CHAL |
|
93886-0 |
|
|
|
|
Observation |
|
|
|
0 |
Breath methane 1h p carb |
|
|
|
|
|
1 hour; 1.0Hr; 1h p carb; 60 min; 60 minutes; 60M; 60min; After; Breath; CHEMISTRY.CHALLENGE TESTING; ExG; Exhaled gas; Exhaled gas (=breath); Gases; p carb; p dose; Percent; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Volfr; Volume fraction |
2.67 |
2.67 |
|
|
|
|
|
|
|
[ppm] |
|
|
|
0 |
| 93887-8 |
Methane/Expired gas^45M post dose carbohydrate |
VFr |
Exhl gas |
Pt |
Qn |
|
|
ACTIVE |
Methane/Expired gas [Volume Fraction] in Exhaled gas --45 minutes post dose carbohydrate |
|
ADD |
DefinitionDescription |
|
|
ppm |
|
|
|
|
|
|
CHAL |
|
93887-8 |
|
|
|
|
Observation |
|
|
|
0 |
Breath methane 45M p carb |
|
|
|
|
|
45M p carb; After; Breath; CHEMISTRY.CHALLENGE TESTING; ExG; Exhaled gas; Exhaled gas (=breath); Gases; p carb; p dose; Percent; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Volfr; Volume fraction |
2.67 |
2.67 |
|
|
|
|
|
|
|
[ppm] |
|
|
|
0 |
